Our Take
A straightforward market access play: Angelini pays 21% premium for proven revenue streams rather than gambling on pipeline drugs.
Why it matters
Rare disease portfolios command premium valuations because of high barriers to competition and predictable cash flows. This deal reflects continued pharma migration toward neuroscience assets after years of neglect.
Do this week
Rare disease portfolio managers: audit your CNS asset valuations against this 7x revenue multiple before Q3 earnings calls.
Angelini pays $31.50 per share for established CNS portfolio
Angelini Pharma will acquire Catalyst Pharmaceuticals for $4.1 billion, paying $31.50 per outstanding share (company announcement). The price represents a 21% premium to Catalyst's prior closing price.
Catalyst brings three marketed CNS medicines to the deal. Firdapse treats Lambert-Eaton myasthenic syndrome, approved in 2018. Fycompa, acquired from Eisai in 2023, treats partial seizures and tonic-clonic seizures in the US market. Agamree is a steroid treatment for Duchenne muscular dystrophy.
The portfolio generated $589 million in revenue last year, up 20% year-over-year (per company guidance). Catalyst projected 2026 revenue between $615-645 million, citing strength in its Firdapse and Agamree franchises.
US market entry drives acquisition logic
The deal hands Angelini direct access to US pharmaceutical markets for the first time. "Entering the U.S. market will allow us to acquire the scale and capabilities needed to continue this journey," CEO Sergio Marullo di Condojanni said.
Angelini currently runs three clinical trials for an experimental epilepsy medicine and has assembled a seizure drug pipeline through recent deals. The Catalyst acquisition provides immediate revenue while those programs advance through development.
The transaction reflects broader pharma interest in neuroscience assets. UCB, Otsuka, and Eli Lilly have each spent billions acquiring CNS-focused companies in 2026 alone.
Revenue multiple sets rare disease valuation benchmark
At $4.1 billion against $589 million in trailing revenue, Angelini paid roughly 7x sales for Catalyst's portfolio. This multiple reflects the defensive characteristics of rare disease franchises: high barriers to generic competition and limited treatment alternatives create predictable cash flows.
The deal structure keeps Catalyst as a wholly owned subsidiary rather than full integration, preserving the US commercial infrastructure that generates the revenue stream. Transaction close is expected in Q3 2026.
For portfolio managers, this acquisition provides a current market reference point for valuing established rare disease assets, particularly those with US commercial presence.